(NASDAQ: MNPR) Monopar Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 4.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.01%.
Monopar Therapeutics's earnings in 2025 is -$17,308,382.On average, 6 Wall Street analysts forecast MNPR's earnings for 2025 to be -$9,944,126, with the lowest MNPR earnings forecast at -$12,771,819, and the highest MNPR earnings forecast at -$7,959,250. On average, 7 Wall Street analysts forecast MNPR's earnings for 2026 to be -$25,499,832, with the lowest MNPR earnings forecast at -$41,585,537, and the highest MNPR earnings forecast at -$12,648,420.
In 2027, MNPR is forecast to generate -$15,995,624 in earnings, with the lowest earnings forecast at -$39,919,648 and the highest earnings forecast at $5,429,566.